Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Elizabeth Halton, Peter Kane, Brigitte Senechal, Eileen M. Geoghegan, Vijay Reddy, Mark S. Berger, Dale Ludwig, Neeta Pandit-Taskar, Craig S. Sauter

Blood (2021) 138 (Supplement 1): 4810.

https://doi.org/10.1182/blood-2021-144994

Published: 2021

Journal Articles

Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

Mohamed M. Hegazi, MD, John G. Harpel, MDPhD, Sara Miao, Dale Ludwig, PhD, Mark S. Berger, MD, Gary J. Schiller, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141132

Published: 2020

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD

Blood (2019) 134 (Supplement_1): 1958.

https://doi.org/10.1182/blood-2019-128838

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova

Blood (2019) 134 (Supplement_1): 5601.

https://doi.org/10.1182/blood-2019-128678

Published: 2019

Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2018-99-111914

Published: 2018

Journal Articles

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

Dale L Ludwig, PhD BS, Mark S. Berger, MD, Dadachova Ekaterina, PhD, Kevin Allen, PhD, Wojciech Dawicki

Blood (2018) 132 (Supplement 1): 5682.

https://doi.org/10.1182/blood-2018-99-119740

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Actinium Labeled Daratumumab Demonstrates Enhanced Killing of Multiple Myeloma Cells over Naked Daratumumab

Mark S. Berger, MD, Keisha Thomas, PhD, Dadachova Ekaterina, PhD, Mackenzie Malo, M.Sc., Rubin Jiao, PhD, Kevin Allen, PhD, Colin Clarke

Blood (2017) 130 (Supplement 1): 4427.

https://doi.org/10.1182/blood.V130.Suppl_1.4427.4427

Published: 2017

Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2611.

https://doi.org/10.1182/blood.V118.21.2611.2611

Published: 2011

Journal Articles

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Jorge E. Cortes, Moshe Talpaz, MD, Hagop M Kantarjian, Hedy Smith, MD, PhD, Dale Bixby, MD, PhD, Usha Rafferty, MS, Mark S. Berger, MD, Scott C. Wise, MS, Tom J. Rutkoski, Ph.D, Bryan Smith, Ph.D, Richard A. Van Etten, MD PhD

Blood (2011) 118 (21): 601.

https://doi.org/10.1182/blood.V118.21.601.601

Published: 2011

Journal Articles

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Andre Goy, MD, Peggy Ford, Tatyana Feldman, MD, Andrew Pecora, Stuart Goldberg, MD, Michele Donato, David Siegel, David Panush, Mark S. Berger, MD

Blood (2007) 110 (11): 2569.

https://doi.org/10.1182/blood.V110.11.2569.2569

Published: 2007

Journal Articles

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia

Robert J. Arceci, Jane Sande, Beverly Lange, Kevin Shannon, Janet Franklin, Raymond Hutchinson, Terry A. Vik, David Flowers, Richard Aplenc, Mark S. Berger, Matthew L. Sherman, Franklin O. Smith, Irwin Bernstein, Eric L. Sievers

Blood (2005) 106 (4): 1183–1188.

https://doi.org/10.1182/blood-2004-10-3821

Published: 2005

Journal Articles

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Michael L. Linenberger, Tom Hong, David Flowers, Eric L. Sievers, Ted A. Gooley, John M. Bennett, Mark S. Berger, Lance H. Leopold, Frederick R. Appelbaum, Irwin D. Bernstein

Blood (2001) 98 (4): 988–994.

https://doi.org/10.1182/blood.V98.4.988

Published: 2001

Journal Articles

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen, Irwin D. Bernstein, Adriaan B. Houtsmuller, Mark S. Berger, Jacques J. M. van Dongen

Blood (2001) 97 (10): 3197–3204.

https://doi.org/10.1182/blood.V97.10.3197

Published: 2001

NARROW

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Actinium Labeled Daratumumab Demonstrates Enhanced Killing of Multiple Myeloma Cells over Naked Daratumumab

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only